source
- Silence Therapeutics moves siRNA drug for polycythemia vera to Phase 3 after Phase 2 successSilence Therapeutics announced that its siRNA candidate divesiran achieved its primary endpoint in a Phase 2 study in patients with polycythemia vera, a rare blood cancer. The trial results showed…
- Bristol Myers Squibb expands Nvidia partnership to build most powerful AI supercomputer for drug discoveryBristol Myers Squibb announced an expanded partnership with Nvidia that will give it the most powerful and energy-efficient Nvidia infrastructure owned by a life-science company. Nvidia says the p…